The Business Times
business-time-50

J&J drug unit to leverage Singapore's biotech hub

'Very lively biotech hub' spurs pharmaceutical arm's external collaborations

google-preferred-sourceAdd BT as a preferred source
Annabeth Leow

Annabeth Leow

Published Sun, Oct 28, 2018 · 09:50 PM

    Singapore

    JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.

    Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".

    TRENDING NOW

    Handled passively, satellite connectivity becomes a service that the telco distributes, while somebody else sets the economics.

    When every phone becomes a satellite phone, what happens to Asia’s telcos?

    After vacating her roles on Oct 1, Lily Ler will become group CFO of the trust’s sponsor, Mapletree Investments.

    Lily Ler to step down as CEO of Mapletree Industrial Trust manager

    The proposed transaction also involves the sale of associated trademarks across Singapore, Malaysia and Myanmar.

    Jardine C&C selling Singapore, Malaysia dealerships to Indonesia’s Chandra Asri for US$221 million gain

    ST Telemedia Global Data Centres is one of the four operators awarded the extra capacity.

    Digital Realty, STT GDC among data centre operators awarded 50 MW of new capacity in Singapore

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More